---
{"dg-publish":true,"permalink":"/USMLE/Cardiology/Heart failure/","tags":["t1"]}
---

# Epidemiology
---


# Etiology
---


# Pathophysiology
---
![L10813.jpg](/img/user/appendix/L10813.jpg)

# Clinical features
---


# Diagnostics
---
## Pathology
- Sputum analysis in patients with [[USMLE/Reproductive/Pulmonary edema\|pulmonary edema]] may show <span style="background:rgba(240, 200, 0, 0.2)">heart failure cells (hemosiderin-containing cells).</span>![Pasted image 20241218090244.png](/img/user/appendix/Pasted%20image%2020241218090244.png)
	- <span style="background:rgba(240, 200, 0, 0.2)">Pulmonary venous congestion may result in intra-alveolar bleeding. Macrophages that subsequently phagocytose the erythrocytes are called “heart failure cells.”</span> These cells may also be detected in the sputum of patients with pulmonary infarction, [[USMLE/MSK/Vasculitides\|vasculitis]], or aspiration of blood.
	- Their color is most likely due to <span style="background:rgba(240, 200, 0, 0.2)">hemosiderin from ingested erythrocytes.</span>
## ECG
![Pasted image 20230723213037.png](/img/user/appendix/Pasted%20image%2020230723213037.png)
- ECG-CHF triad
	1. Low QRS voltages in the limb leads (caused by peripheral edema in CHF patients)
	2. Left ventricular hypertrophy (prominent precordial QRS voltages)
	3. Very slow R wave progression in chest leads (rS in V4)


# Treatment
---

| Agent                                                                                                                                                          | Mortality Benefit                                     |
| -------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------------------------------------------------- |
| Angiotensin receptor-neprilysin inhibitor (e.g., sacubitril-valsartan) OR ACE inhibitor (e.g., lisinopril) OR Angiotensin II receptor blocker (e.g., losartan) | Yes                                                   |
| [[USMLE/Cardiology/Beta blockers\|Beta blocker]] (e.g., metoprolol, carvedilol)                                                                                                 | Yes                                                   |
| Mineralocorticoid receptor antagonist (e.g., <span style="background:rgba(240, 200, 0, 0.2)">spironolactone</span>, eplerenone)                                | Yes                                                   |
| Sodium-glucose cotransporter-2 inhibitor (e.g., dapagliflozin, empagliflozin)                                                                                  | Yes                                                   |
| [[USMLE/Pharmacology/Diuretics\|Diuretic]] (e.g., furosemide, metolazone)                                                                                                         | No, only improves symptoms & reduces hospitalization. |
| [[USMLE/Cardiology/Cardiac glycosides\|Digoxin]]                                                                                                                                | No, only reduces hospitalization.                     |

>[!tip] Explanation
>- Spironolactone also <span style="background:rgba(240, 200, 0, 0.2)">block the deleterious effect of aldosterone on the heart</span>, causing regression of myocardial fibrosis and <span style="background:rgba(240, 200, 0, 0.2)">improvement in ventricular remodeling</span>.

## RAAS inhibitors
- <span style="background:rgba(240, 200, 0, 0.2)">Angiotensin receptor-neprilysin inhibitors (ARNIs)</span>
	- Drug names: <span style="background:rgba(240, 200, 0, 0.2)">sacubitril/valsartan </span>
		- To <span style="background:rgba(240, 200, 0, 0.2)">block the vasoconstrictive effect of angiotensin II accumulation, sacubitril needs to be combined with an ARB</span>.![highresdefault_L25942.jpg](/img/user/appendix/highresdefault_L25942.jpg)
			- <span style="background:rgba(240, 200, 0, 0.2)">Neprilysin</span> is a zinc-dependent metalloprotease that cleaves peptides at the amino side of hydrophobic residues and <span style="background:rgba(240, 200, 0, 0.2)">inactivates several peptide hormones</span> including glucagon, enkephalins, substance P, neurotensin, oxytocin, and bradykinin.
	- Indication: Stage C or D HFrEF (preferred initial agent for RAAS inhibition)
